Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 7/20 | 0.43 |
| ▸ | MERTK | Q12866 | 7/20 | 0.43 |
| ▸ | GAS6 | Q14393 | 4/20 | 0.43 |
| ▸ | AXL | P30530 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558940 | 1.00 | TYRO3 (0.43) | TYRO3MERTKGAS6AXLMAPK1 | |
| SCHEMBL10166201 | 1.00 | TYRO3 (0.43) | TYRO3MERTKGAS6AXLMAPK1 | |
| SCHEMBL559464 | 0.83 | HCAR3 (0.44) | CCNT1MAPK14 | |
| SCHEMBL559465 | 0.83 | HCAR3 (0.44) | CCNT1MAPK14 | |
| SCHEMBL10166205 | 0.83 | HCAR3 (0.44) | CCNT1MAPK14 | |
| SCHEMBL12378876 | 0.75 | MAPK14 (0.49) | CCNT1MAPK14 | |
| SCHEMBL14391692 | 0.75 | ALOX5AP (0.48) | MEN1CACNA1BAPBA1KMT2A | |
| SCHEMBL558762 | 0.73 | LCK (0.42) | CCNT1MAPK14FLT3 | |
| SCHEMBL558920 | 0.73 | LCK (0.42) | CCNT1MAPK14FLT3 | |
| SCHEMBL558761 | 0.73 | LCK (0.42) | CCNT1MAPK14FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | TYRO3 691/4885MERTK 2882/4885GAS6 2254/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | TYRO3 691/4885MERTK 2882/4885GAS6 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.